Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 240 (TMEM240) is a small, evolutionarily conserved membrane protein encoded by the TMEM240 gene (previously C1orf70), located on chromosome 1p36.33[5][7][8]. It is highly expressed in brain tissue, particularly in the cerebellum and other regions involved in motor control[3][4][5]. Mutations in TMEM240 cause spinocerebellar ataxia type 21 (SCA21), a rare autosomal dominant neurodegenerative disorder characterized by early-onset, slowly progressive cerebellar ataxia, cognitive impairment, and variable neurodevelopmental delay[2][4][6][8]. The exact physiological and molecular function of TMEM240 remains unclear, but it is believed to play a role in neuronal structure and function. Pathogenic variants (typically missense or nonsense mutations) disrupt normal protein function, leading to the SCA21 phenotype[2][6][8]. TMEM240 is not currently considered a therapeutic target, and no drugs are known to modulate its activity for disease treatment.
No established drugs; mechanism of pathogenesis is through gene mutations leading to protein dysfunction causing SCA21.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 240 (TMEM240).